217 related articles for article (PubMed ID: 28786282)
1. [BISPHOSPHONATES AS A PREVENTATIVE TREATMENT FOR OSTEOPOROTIC HIP FRACTURES: A MIXED BLESSING].
Barak U; Rosenthal Y; Arami A; Kosashvili Y; Velkes S
Harefuah; 2017 Jul; 156(7):433-437. PubMed ID: 28786282
[TBL] [Abstract][Full Text] [Related]
2. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment.
Yeh WL; Su CY; Chang CW; Chen CH; Fu TS; Chen LH; Lin TY
BMC Musculoskelet Disord; 2017 Dec; 18(1):527. PubMed ID: 29237448
[TBL] [Abstract][Full Text] [Related]
3. Retrospective review of patients with atypical bisphosphonate related proximal femoral fractures.
Phillips HK; Harrison SJ; Akrawi H; Sidhom SA
Injury; 2017 Jun; 48(6):1159-1164. PubMed ID: 28410753
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.
Black DM; Kelly MP; Genant HK; Palermo L; Eastell R; Bucci-Rechtweg C; Cauley J; Leung PC; Boonen S; Santora A; de Papp A; Bauer DC; ;
N Engl J Med; 2010 May; 362(19):1761-71. PubMed ID: 20335571
[TBL] [Abstract][Full Text] [Related]
5. Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates.
Puhaindran ME; Farooki A; Steensma MR; Hameed M; Healey JH; Boland PJ
J Bone Joint Surg Am; 2011 Jul; 93(13):1235-42. PubMed ID: 21776577
[TBL] [Abstract][Full Text] [Related]
6. Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates.
Black DM; Geiger EJ; Eastell R; Vittinghoff E; Li BH; Ryan DS; Dell RM; Adams AL
N Engl J Med; 2020 Aug; 383(8):743-753. PubMed ID: 32813950
[TBL] [Abstract][Full Text] [Related]
7. Atypical fractures as a potential complication of long-term bisphosphonate therapy.
Sellmeyer DE
JAMA; 2010 Oct; 304(13):1480-4. PubMed ID: 20924014
[TBL] [Abstract][Full Text] [Related]
8. Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Pazianas M; Abrahamsen B; Wang Y; Russell RG
Osteoporos Int; 2012 Dec; 23(12):2873-84. PubMed ID: 22431012
[TBL] [Abstract][Full Text] [Related]
9. Salvage of failed osteosynthesis for an atypical subtrochanteric femoral fracture associated with long-term bisphosphonate treatment using a 95° angled blade plate.
Kim SM; Rhyu KH; Lim SJ
Bone Joint J; 2018 Nov; 100-B(11):1511-1517. PubMed ID: 30418051
[TBL] [Abstract][Full Text] [Related]
10. Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.
Nieves JW; Cosman F
Curr Osteoporos Rep; 2010 Mar; 8(1):34-9. PubMed ID: 20425089
[TBL] [Abstract][Full Text] [Related]
11. Atypical femoral fractures and bisphosphonate treatment: experience in two large United Kingdom teaching hospitals.
Thompson RN; Phillips JR; McCauley SH; Elliott JR; Moran CG
J Bone Joint Surg Br; 2012 Mar; 94(3):385-90. PubMed ID: 22371548
[TBL] [Abstract][Full Text] [Related]
12. Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.
Rizzoli R; Akesson K; Bouxsein M; Kanis JA; Napoli N; Papapoulos S; Reginster JY; Cooper C
Osteoporos Int; 2011 Feb; 22(2):373-90. PubMed ID: 21085935
[TBL] [Abstract][Full Text] [Related]
13. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
Soen S
Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
[TBL] [Abstract][Full Text] [Related]
14. Adherence With Bisphosphonates and Long-Term Risk of Hip Fractures: A Nested Case-Control Study Using Real-World Data.
Shalev V; Sharman Moser S; Goldshtein I; Yu J; Weil C; Ish-Shalom S; Rouach V; Chodick G
Ann Pharmacother; 2017 Sep; 51(9):757-767. PubMed ID: 28535690
[TBL] [Abstract][Full Text] [Related]
15. [Atypical subtrochanteric femur fracture under alendronate therapy in spite of an intramedullar implant].
Sobotta HP; Gösling T
Unfallchirurg; 2017 Feb; 120(2):171-175. PubMed ID: 27812727
[TBL] [Abstract][Full Text] [Related]
16. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
17. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
[TBL] [Abstract][Full Text] [Related]
18. Atypical femoral fractures related to bisphosphonate use: A comprehensive review of 19 patients.
Şahin K; Ergin ON; Bayram S; Akgül T
Ulus Travma Acil Cerrahi Derg; 2019 Nov; 25(6):603-610. PubMed ID: 31701502
[TBL] [Abstract][Full Text] [Related]
19. Alendronate improves screw fixation in osteoporotic bone.
Moroni A; Faldini C; Hoang-Kim A; Pegreffi F; Giannini S
J Bone Joint Surg Am; 2007 Jan; 89(1):96-101. PubMed ID: 17200316
[TBL] [Abstract][Full Text] [Related]
20. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use.
Weil YA; Rivkin G; Safran O; Liebergall M; Foldes AJ
J Trauma; 2011 Jul; 71(1):186-90. PubMed ID: 21610533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
